DR. CHIL-YONG KANG | Concordia University Lecture Series on HIV/AIDS

427 lượt xem
Xuất bản 18/08/2015
Search for the HIV Vaccine: One of the most challenging problems in infectious diseases The Concordia University Community Lecture Series on HIV/AIDS presents: Dr. Chil-Yong Kang, Virologist, Western University Thursday October 30th 2014 You’re invited to the first edition of he 22nd Annual Concordia University Community Lecture Series on HIV/AIDS featuring Dr. Chil-Yong Kang of the Schulich School of Medicine. He will be speaking on his research into the HIV vaccine, now entering Phase II of human trials. The vaccine, SAV001-H, and its developer, Dr. Kang, have made headlines internationally as this cost effective Canadian invention will likely alter the course of the HIV epidemic which has claimed 36 million lives with another 35 million living with the virus. Dr. Kang will explore the challenges associated with the development of an HIV vaccine as well as explore potential impacts. SAV001-H is the first preventive HIV vaccine using a killed or "dead version" of HIV-1 virus. It is widely believed that this previously risky approach is the only biomedical way forward in terms of a vaccine. What are the differences between the vaccine and other preventative mechanisms and how does this development differentially affect the multiple faces of the epidemic? Training under Nobel Laureate Dr. Howard Temin, Dr. Kang has himself received numerous prizes that recognize his achievements in virology, such as the Order of Korea in Science and Technology (2002), and the Lifetime Achievement Award from Western University (2009). For more information contact: hivaids@concordia.ca
Concordia University College/University Public Lecture AIDS Disease Or Medical Condition HIV Vaccine Condition Prevention Factors Gangline Media Dr Chil-Yong Kang Big Pharma Pharmaceutical Industry Industry
left banner
You did not use the site, Click here to remain logged. Timeout: 60 second